Firm Secures Major Patent Litigation Win for Janssen Pharmaceuticals
The Firm obtained a significant trial victory for our client, Johnson & Johnson (J&J) subsidiaries Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica, NV, when the U.S. District Court for the District of New Jersey issued an order in our client’s favor in a Hatch-Waxman patent litigation. For nearly four years, we have represented subsidiary Janssen Pharmaceuticals in a patent infringement lawsuit brought against generic drug manufacturer Teva Pharmaceuticals USA, Inc. over its proposed generic version of Janssen’s long-acting injectable antipsychotic drug Invega Sustenna®. Invega Sustenna is a blockbuster medicine, with over $1.5 billion in annual sales in the United States. At stake in the case were nearly 10 years of patent protection; the patent in suit was the sole remaining patent covering Invega Sustenna®. Following a three-week bench trial in October 2020, the District Court of New Jersey issued an order rejecting all of Teva’s allegations of invalidity. The district court’s decision confirms the inventiveness of the work that led to Invega Sustenna and the importance of the medicine and its dosing regimen to the treatment of schizophrenia, and enables J&J to continue to reinvest in the development of new treatments.
To read the court’s Opinion, click here.